CU20120098A7 - Isoquinolinonas y quinazolinonas sustituidas - Google Patents

Isoquinolinonas y quinazolinonas sustituidas

Info

Publication number
CU20120098A7
CU20120098A7 CU2012000098A CU20120098A CU20120098A7 CU 20120098 A7 CU20120098 A7 CU 20120098A7 CU 2012000098 A CU2012000098 A CU 2012000098A CU 20120098 A CU20120098 A CU 20120098A CU 20120098 A7 CU20120098 A7 CU 20120098A7
Authority
CU
Cuba
Prior art keywords
isoquinolinones
quinazolinones
replaced
formula
mdm4
Prior art date
Application number
CU2012000098A
Other languages
English (en)
Other versions
CU24130B1 (es
Inventor
Joerg Berghausen
Nicole Buschmann
Pascal Furet
Francois Gessier
Lisztwan Joanna Hergovich
Philipp Holzer
Edgar Jacoby
Joerg Kallen
Keiichi Masuya
Soldermann Carole Pissot
Haixia Ren
Stefan Stutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45093718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120098(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/EP2010/070364 external-priority patent/WO2011076786A1/en
Publication of CU20120098A7 publication Critical patent/CU20120098A7/es
Publication of CU24130B1 publication Critical patent/CU24130B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a heterociclos bicíclicos que contienen nitrógeno sustituidos de la fórmula (I): ESPACIO PARA LA FÓRMULA en donde Z es CH2 o N-R4, y X, R1, R2, R4, R6, R7 y n son como se definen en la descripción. Estos compuestos son adecuados para el tratamiento de un trastorno o enfermedad que sea mediada por la actividad de MDM2 y/o MDM4, o variantes de los mismos.
CU2012000098A 2009-12-22 2010-12-21 Isoquinolinonas y quinazolinonas sustituidas CU24130B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28899209P 2009-12-22 2009-12-22
CN2010078927 2010-11-19
PCT/EP2010/070364 WO2011076786A1 (en) 2009-12-22 2010-12-21 Substituted isoquinolinones and quinazolinones

Publications (2)

Publication Number Publication Date
CU20120098A7 true CU20120098A7 (es) 2012-10-15
CU24130B1 CU24130B1 (es) 2015-09-29

Family

ID=45093718

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000098A CU24130B1 (es) 2009-12-22 2010-12-21 Isoquinolinonas y quinazolinonas sustituidas

Country Status (34)

Country Link
US (2) US9073898B2 (es)
EP (1) EP2640467B1 (es)
JP (1) JP5667308B2 (es)
KR (1) KR101561750B1 (es)
AR (1) AR083905A1 (es)
AU (1) AU2011331095B2 (es)
BR (1) BR112013011966A2 (es)
CA (1) CA2816810A1 (es)
CO (1) CO6801719A2 (es)
CU (1) CU24130B1 (es)
CY (1) CY1116002T1 (es)
DK (1) DK2640467T3 (es)
EC (1) ECSP13012628A (es)
ES (1) ES2528376T3 (es)
GT (1) GT201300132A (es)
HR (1) HRP20150231T1 (es)
IL (1) IL226182A0 (es)
MA (1) MA34666B1 (es)
ME (1) ME02099B (es)
MX (1) MX336634B (es)
MY (1) MY160880A (es)
NZ (1) NZ610296A (es)
PE (1) PE20140420A1 (es)
PH (1) PH12013500979A1 (es)
PL (1) PL2640467T3 (es)
PT (1) PT2640467E (es)
RS (1) RS53770B1 (es)
RU (1) RU2013127661A (es)
SG (1) SG190186A1 (es)
SI (1) SI2640467T1 (es)
SM (1) SMT201500059B (es)
TW (1) TWI520950B (es)
WO (1) WO2012066095A1 (es)
ZA (1) ZA201303155B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP3412675A1 (en) 2013-05-27 2018-12-12 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний
CN105848656B (zh) * 2013-12-23 2019-10-25 诺华股份有限公司 药物组合
KR20160100975A (ko) * 2013-12-23 2016-08-24 노파르티스 아게 제약 조합물
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
TWI750129B (zh) 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
US20180318275A1 (en) * 2015-08-28 2018-11-08 Novartis Ag Combination therapy using pi3k inhibitor and mdm2 inhibitor
WO2017037579A1 (en) 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
KR101838687B1 (ko) 2016-01-26 2018-03-15 한국생명공학연구원 나노포어를 이용한 단백질-단백질 상호작용 저해제 스크리닝 방법
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
WO2019053595A1 (en) 2017-09-12 2019-03-21 Novartis Ag INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA
EP3694518A1 (en) 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829420A (en) 1970-07-13 1974-08-13 Sumitomo Chemical Co 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
US4099002A (en) 1970-12-23 1978-07-04 Sumitomo Chemical Company, Limited Quinazolinone derivatives and a process for production thereof
JPS4822715B1 (es) 1970-12-28 1973-07-07
JPS5427356B2 (es) 1972-03-31 1979-09-10
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4258187A (en) 1977-06-16 1981-03-24 E. I. Du Pont De Nemours And Company Process for preparing quinazolinone oxides
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3420799A1 (de) 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0958305B1 (en) 1996-07-05 2008-06-04 Cancer Research Technology Limited Inhibitions of the interaction between p53 and mdm2
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
AU4141697A (en) 1996-09-06 1998-03-26 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
CN1660840A (zh) 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
WO2000066560A1 (en) 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US20060189511A1 (en) 2002-05-13 2006-08-24 Koblish Holly K Method for cytoprotection through mdm2 and hdm2 inhibition
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US20040213264A1 (en) 2003-04-25 2004-10-28 Nortel Networks Limited Service class and destination dominance traffic management
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
WO2005027882A1 (en) 2003-09-22 2005-03-31 Bionetworks Gmbh Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
US20080153791A1 (en) 2005-03-18 2008-06-26 Onpharm Gmbh 11Beta -Hydroxysteroid Dehydrogenases
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
WO2008034039A2 (en) * 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones

Also Published As

Publication number Publication date
PT2640467E (pt) 2015-03-12
ES2528376T3 (es) 2015-02-09
US20130245036A1 (en) 2013-09-19
IL226182A0 (en) 2013-07-31
BR112013011966A2 (pt) 2016-08-30
US9073898B2 (en) 2015-07-07
JP2013542968A (ja) 2013-11-28
NZ610296A (en) 2014-08-29
AR083905A1 (es) 2013-04-10
KR101561750B1 (ko) 2015-10-19
AU2011331095B2 (en) 2016-03-10
CA2816810A1 (en) 2012-05-24
WO2012066095A1 (en) 2012-05-24
EP2640467A1 (en) 2013-09-25
HK1184091A1 (en) 2014-01-17
MY160880A (en) 2017-03-31
US8969351B2 (en) 2015-03-03
PE20140420A1 (es) 2014-04-02
MX336634B (es) 2016-01-26
EP2640467B1 (en) 2014-12-17
CO6801719A2 (es) 2013-11-29
JP5667308B2 (ja) 2015-02-12
AU2011331095A1 (en) 2013-05-30
MX2013005631A (es) 2013-07-05
MA34666B1 (fr) 2013-11-02
CU24130B1 (es) 2015-09-29
US20120129871A1 (en) 2012-05-24
KR20130087572A (ko) 2013-08-06
RS53770B1 (sr) 2015-06-30
PH12013500979A1 (en) 2018-04-11
RU2013127661A (ru) 2014-12-27
ME02099B (me) 2016-02-20
SMT201500059B (it) 2015-05-05
ZA201303155B (en) 2014-01-29
TWI520950B (zh) 2016-02-11
ECSP13012628A (es) 2013-07-31
TW201302725A (zh) 2013-01-16
HRP20150231T1 (xx) 2015-03-27
SG190186A1 (en) 2013-06-28
DK2640467T3 (en) 2015-03-02
PL2640467T3 (pl) 2015-05-29
SI2640467T1 (sl) 2015-04-30
GT201300132A (es) 2014-06-09
CY1116002T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
CU20120098A7 (es) Isoquinolinonas y quinazolinonas sustituidas
NI201200111A (es) Isoquinolinonas y quinazolinonas sustituidas
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CO6390057A2 (es) Indazoles oxazol sustituidos como inhibidores de pi3-quinasa
UY33969A (es) Inhibidores tricíclicos fusionados dobles de las cdk 4/6 y de la flt3
DOP2010000079A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
UY34261A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos
BR112012024117A2 (pt) inibidores de pirrolopirazina quinase
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
UY31472A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
DOP2011000009A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
DOP2010000078A (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
CR20130087A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
CU24325B1 (es) Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores
ECSP10010409A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
ECSP089025A (es) Tratamiento de trastornos gastrointestinales con antagonistas de cgrp
CR20110368A (es) Compuestos de quinazolina sustituidos
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων
BRPI0916657A2 (pt) pirrolidin-3-ilmetil-amina como antagonistas de orexina
GT200600422A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY31840A (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
CU23955B1 (es) PIRIMIDINAS BICÍCLICAS FUSIONADAS COMO INHIBIDORES EFECTIVOS DE LA VÍA Pi3K/Akt

Legal Events

Date Code Title Description
FG Grant of patent